A Single-centre, Open-label, Five-way Crossover Study in Healthy Female Participants to Assess the Pharmacokinetics of Nasally Administered Formulations of Teriparatide Compared to a Subcutaneous Injection.
Phase of Trial: Phase I
Latest Information Update: 27 Feb 2017
Price : $35 *
At a glance
- Drugs Teriparatide (Primary) ; Teriparatide (Primary)
- Indications Postmenopausal osteoporosis
- Focus Pharmacokinetics
- Acronyms NINTTO
- 21 Jun 2014 Accrual to date is 100% according to United Kingdom Clinical Research Network.
- 15 Apr 2014 Status changed from not yet recruiting to recruiting, according to a Critical Pharmaceuticals media release.
- 18 Aug 2013 New trial record